ACR2022 - Day 2.4
Episode description
AI Future of Sacroiliitis Assessment Dr. Rachel Tate speaks with Dr. Fabian Proft about Abstract 0383 at ACR22 Convergence.
Can I stop Methotrexate in RA? Dr. Janet Pope and Dr. Charis Meng discuss Abstract 0916 at ACR22 Convergence. Abstract 0916: Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
CAR-T Therapies in Antiphospholipid Antibody Syndrome Dr. Michael Putman and Dr. Maximilian Konig discuss abstract 1677 at ACR22 Convergence. Abstract 1677: Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells Copays Reduce Adherence to SLE Medications Dr. Michael Putman reports on abstract 1115 at ACR22 Convergence in Philadelphia, PA.
Copays Reduce Adherence to SLE Medications Dr. Michael Putman reports on abstract 1115 at ACR22 Convergence in Philadelphia, PA.
Does Race play a role in Mycophenolate Response in Scleroderma? Dr. Eric Dein speaks with Dr. Lauren Smith about abstract 0521 at ACR22 Convergence in Philadelphia, PA. Abstract 0521: Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis
Fertility issues in SpA Dr. Sheila Reyes speaks with Dr. Sabrina Hamroun about abstract 1673 at ACR22 Convergence. Abstract 1673: Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort
Opioid use in PsA and SpA Dr. Eric Dein discusses Abstract 1012 at ACR22 Convergence
PsA and SPA: Cyclers, Switchers, Who is the Winner? Dr. Aurelie Najm discusses abstracts 1499 and 1600 at ACR22 Convergence in Philadelphia, PA.
Remibrutinib in Sjogren's Syndrome Dr. Michael Putman reports on abstract 1113 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study